Mott David M insider trades
Mott David M has filed 49 Form 4s with the SEC that we hold, for Ardelyx, INC. (ARDX) (Director), MRSN (Director), Novavax INC (NVAX) (Director) and EPZM (Director), among 6 companies in all. Across all of them we count 19 purchases worth $10.0M and 5 sales worth $6.3M reported on Form 4. In the last 12 months: 1 purchase ($1.9M) and 0 sales ($0). The largest single trade was a sale of 7,744 shares of Novavax INC worth $2.0M, dated 2021-09-23. The first filing on our record is dated 2021-07-01 and the latest 2026-06-23.
Ardelyx, INC. (ARDX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-11-17 | P, purchase reported on Form 4 | 567,000 | $997.9K | 2022-11-17 |
| 2024-11-13 | P, purchase reported on Form 4 | 215,868 | $997.3K | 2024-11-14 |
| 2024-12-19 | P, purchase reported on Form 4 | 213,300 | $996.1K | 2024-12-23 |
| 2025-01-21 | P, purchase reported on Form 4 | 199,000 | $993.0K | 2025-01-22 |
| 2025-02-24 | P, purchase reported on Form 4 | 77,729 | $388.6K | 2025-02-26 |
| 2025-05-02 | P, purchase reported on Form 4 | 381,377 | $1.6M | 2025-05-05 |
| 2025-05-15 | P, purchase reported on Form 4 | 100,000 | $329.0K | 2025-05-19 |
| 2025-06-09 | P, purchase reported on Form 4 | 200,000 | $738.0K | 2025-06-11 |
| 2025-06-16 | P, purchase reported on Form 4 | 200,000 | $726.0K | 2025-06-18 |
| 2026-02-20 | P, purchase reported on Form 4 | 333,333 | $1.9M | 2026-02-23 |
MRSN
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Novavax INC (NVAX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-09-23 | S, sale reported on Form 4 | 2,732 | $695.2K | 2021-09-24 |
| 2021-09-23 | S, sale reported on Form 4 | 7,744 | $2.0M | 2021-09-24 |
| 2021-09-23 | S, sale reported on Form 4 | 1,200 | $306.5K | 2021-09-24 |
| 2021-09-23 | S, sale reported on Form 4 | 7,557 | $1.9M | 2021-09-24 |
| 2021-09-23 | S, sale reported on Form 4 | 5,728 | $1.4M | 2021-09-24 |
EPZM
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Adaptimmune Therapeutics PLC (ADAP)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Enliven Therapeutics, Inc. (IMRA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-02-10 | P, purchase reported on Form 4 | 8,753 | $11.3K | 2022-02-14 |
| 2022-02-11 | P, purchase reported on Form 4 | 14,573 | $17.9K | 2022-02-14 |
| 2022-02-14 | P, purchase reported on Form 4 | 8,500 | $10.0K | 2022-02-14 |
| 2022-02-15 | P, purchase reported on Form 4 | 19,552 | $23.5K | 2022-02-17 |
| 2022-02-16 | P, purchase reported on Form 4 | 11,779 | $14.1K | 2022-02-17 |
| 2022-02-17 | P, purchase reported on Form 4 | 14,595 | $17.1K | 2022-02-17 |
| 2022-02-18 | P, purchase reported on Form 4 | 50,398 | $65.5K | 2022-02-23 |
| 2022-02-22 | P, purchase reported on Form 4 | 65,817 | $102.7K | 2022-02-23 |
| 2022-02-23 | P, purchase reported on Form 4 | 35,257 | $51.5K | 2022-02-23 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1219871) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms